<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="perrault" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">perrault</book-part-id>
      <title-group>
        <title>Perrault Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Newman</surname>
            <given-names>William G</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Manchester Centre for Genomic Medicine<break/>University of Manchester and Central Manchester University Hospitals NHS Foundation Trust<break/>Manchester, United Kingdom</aff>
          <email>william.newman@manchester.ac.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Friedman</surname>
            <given-names>Thomas B</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Laboratory of Molecular Genetics<break/>National Institute on Deafness and Other Communication Disorders, NIH<break/>John David Porter Neuroscience Research Center, NIH<break/>Bethesda, Maryland</aff>
          <email>friedman@nidcd.nih.gov</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Conway</surname>
            <given-names>Gerard S</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Institute for Women's Health<break/>University College London<break/>London, United Kingdom</aff>
          <email>g.conway@ucl.ac.uk</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>25</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="pbd" document-type="chapter">Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="perry" document-type="chapter">Perry Syndrome</related-object>
      <abstract id="perrault.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Perrault syndrome is characterized by sensorineural hearing loss (SNHL) in males and females, and ovarian dysfunction in females. The SNHL is bilateral and ranges in severity from moderate with early-childhood onset to profound with prelingual (congenital) onset to moderate with early-childhood onset. When onset is in early childhood, hearing loss can be progressive. Ovarian dysfunction ranges from gonadal dysgenesis (absent or streak gonads) manifesting as primary amenorrhea to primary ovarian insufficiency (POI) defined as cessation of menses before age 40 years. Fertility in affected males is reported as normal (although the number of reported males is limited). Neurologic features described in some affected women include developmental delay or intellectual disability, cerebellar ataxia, and motor and sensory peripheral neuropathy.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of Perrault syndrome is based on the clinical findings of SNHL in men and women, and ovarian dysfunction in women with a 46,XX karyotype. The diagnosis is confirmed by the presence of biallelic pathogenic variants in one of four genes (<italic toggle="yes">HARS2, HSD17B4, LARS2,</italic> or <italic toggle="yes">CLPP</italic>); to date, however, biallelic pathogenic variants in one of these four genes have been identified in individuals in seven families only.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Hearing loss should be assessed and treated by a multidisciplinary team including an audiologist and otolaryngologist. Possible interventions for those with hearing loss include special educational resources, hearing aids, vibrotactile devices, and cochlear implantation. Cochlear implantation is an option for children older than 12 months with severe-to-profound hearing loss. Primary amenorrhea is treated in adolescents in collaboration with a pediatric endocrinologist in the usual manner first to induce puberty and then to mimic the menstrual cycle and maintain bone health. Assisted reproduction through in vitro fertilization using donor eggs is a consideration for women with gonadal dysgenesis; oocyte cryopreservation can be considered in women at risk for primary ovarian insufficiency.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> In consultation with a reproductive endocrinologist, estrogen replacement treatment should be combined with progesterone to reduce the risk for endometrial cancer.</p>
          <p><italic toggle="yes">Surveillance:</italic> For women with primary amenorrhea: during induction of puberty, follow up every three months for staging of pubertal development and adjustment of estrogen dose. For women on maintenance estrogen replacement therapy: annual follow up as well as approximately every five-year assessment of bone density. Routine audiologic assessments when hearing loss is mild to moderate; no follow up or audiologic assessments when hearing loss is profound. For children with hearing impairment: monitor development</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Avoid: ototoxic medication (e.g., aminoglycosides) if alternatives are available; exposure to loud noise, which can exacerbate hearing loss.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> It is appropriate to evaluate the older and younger sibs of a proband in order to identify as early as possible those who would benefit from treatment and preventive measures (e.g., early intervention in young children with profound hearing loss).</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Perrault syndrome is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk require prior molecular identification of the pathogenic variants causing Perrault syndrome in the family.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="perrault.Diagnosis">
        <title>Diagnosis</title>
        <p>No formal diagnostic criteria have been published for Perrault syndrome.</p>
        <p><bold>The diagnosis of Perrault syndrome is typically established</bold> by the presence of:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Sensorineural hearing loss (SNHL) in men and women.</bold> SNHL is bilateral and ranges in severity from moderate with early-childhood onset to profound with prelingual (congenital) onset. The hearing threshold increase can be variable but primarily affects low frequencies, which is referred to as an upsloping hearing loss. When presenting in early childhood, hearing loss can be progressive.</p>
            <list list-type="bullet">
              <list-item>
                <p>SNHL may be apparent from birth in infants who fail neonatal screening tests.</p>
              </list-item>
              <list-item>
                <p>In older children SNHL can be demonstrated on an audiogram, which will show similar hearing thresholds for both bone and air conduction.</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>Ovarian dysfunction in women with a 46,XX karyotype.</bold> The spectrum of ovarian dysfunction extends across a continuum from mild (primary ovarian insufficiency [POI]) to severe (ovarian dysgenesis).</p>
            <list list-type="bullet">
              <list-item>
                <p>POI is defined as cessation of menses before age 40 years, with raised levels of follicle stimulating hormone (FSH) and reduced serum estrogen concentration.</p>
              </list-item>
              <list-item>
                <p>Ovarian dysgenesis is a developmental disorder characterized by loss of germ and supportive cells (e.g., granulosa and theca) in the gonads. The ovaries are dysplastic, streak, or absent. Serum concentration of estrogen is decreased with a consequent elevation in serum concentration of the two gonadotropins, lutenizing hormone (LH) and follicle stimulating hormone (FSH) (i.e., with hypergonadotropic hypogonadism). The uterus is rudimentary and pre-pubertal on ultrasound examination.</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>Family history</bold> consistent with autosomal recessive inheritance (including parental consanguinity).</p>
          </list-item>
        </list>
        <p>Note: Sensorineural hearing loss is usually the initial manifestation of Perrault syndrome. The diagnosis will not be considered, based on clinical findings alone, in males who do not have an affected sister. The initial diagnosis will not be made based on clinical findings alone, in females, until delayed pubertal development is noted, usually in the teenage years.</p>
        <p><bold>The diagnosis of Perrault syndrome is confirmed</bold> by the presence of biallelic pathogenic variants in one of four genes: <italic toggle="yes">HARS2, HSD17B4, LARS2,</italic> or <italic toggle="yes">CLPP</italic> (see <xref ref-type="table" rid="perrault.T.summary_of_molecular_genetic">Table 1</xref>). To date, however, biallelic pathogenic variants in these four genes have been observed only in individuals from seven reported families; in the majority of cases, the molecular basis of Perrault syndrome is unknown. In one series, these four genes were implicated in four of 15 families with Perrault syndrome [<xref ref-type="bibr" rid="perrault.REF.pierce.2013.614">Pierce et al 2013</xref>]. Thus, failure to detect pathogenic variants in one of these four genes suggests either the presence of a variant in a gene region not sequenced (e.g., enhancer, promoter, intron), mutation of an as-yet-unidentified gene, or inaccurate clinical diagnosis (see <xref ref-type="sec" rid="perrault.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
        <p>A genetic testing strategy that can be employed is use of a multi-gene panel that includes these four genes and other genes of interest (see <xref ref-type="sec" rid="perrault.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time.</p>
        <table-wrap id="perrault.T.summary_of_molecular_genetic" orientation="portrait" position="anchor">
          <label>Table 1. </label>
          <caption>
            <p>Summary of Molecular Genetic Testing Used in Perrault Syndrome</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                <th id="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Number of Families with Perrault Syndrome Attributed to Mutation of This Gene</th>
                <th id="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <italic toggle="yes">HARS2</italic>
                </td>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">1&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <italic toggle="yes">LARS2</italic>
                </td>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">2&#x000a0;<sup>5</sup></td>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <italic toggle="yes">HSD17B4</italic>
                </td>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">1&#x000a0;<sup>6</sup></td>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <italic toggle="yes">CLPP</italic>
                </td>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">3&#x000a0;<sup>7</sup></td>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>8,&#x000a0;9</sup></td>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                <td headers="hd_h_perrault.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="perrault.TF.1.1">
              <label>1. </label>
              <p>See <related-object source-id="gene" document-id="perrault" object-id="perrault.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="perrault.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
            </fn>
            <fn id="perrault.TF.1.2">
              <label>2. </label>
              <p>
                <xref ref-type="bibr" rid="perrault.REF.pierce.2011.6543">Pierce et al [2011]</xref>
              </p>
            </fn>
            <fn id="perrault.TF.1.3">
              <label>3. </label>
              <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
            </fn>
            <fn id="perrault.TF.1.4">
              <label>4. </label>
              <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), CNV detection using massively parallel sequencing and chromosomal microarray (CMA) that includes this gene/chromosome segment. To date no pathogenic deletions or duplications have been described in the genes causing Perrault syndrome.</p>
            </fn>
            <fn id="perrault.TF.1.5">
              <label>5. </label>
              <p>
                <xref ref-type="bibr" rid="perrault.REF.pierce.2013.614">Pierce et al [2013]</xref>
              </p>
            </fn>
            <fn id="perrault.TF.1.6">
              <label>6. </label>
              <p>
                <xref ref-type="bibr" rid="perrault.REF.pierce.2010.282">Pierce et al [2010 ]</xref>
              </p>
            </fn>
            <fn id="perrault.TF.1.7">
              <label>7. </label>
              <p>
                <xref ref-type="bibr" rid="perrault.REF.jenkinson.2013.605">Jenkinson et al [2013]</xref>
              </p>
            </fn>
            <fn id="perrault.TF.1.8">
              <label>8. </label>
              <p>
                <xref ref-type="bibr" rid="perrault.REF.jenkinson.2012.974">Jenkinson et al [2012]</xref>
              </p>
            </fn>
            <fn id="perrault.TF.1.9">
              <label>9. </label>
              <p>The molecular basis of Perrault syndrome is unknown for the majority of cases</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="perrault.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="perrault.Clinical_Description">
          <title>Clinical Description</title>
          <p>Perrault syndrome is characterized by sensorineural hearing loss (SNHL) in males and females and ovarian dysfunction in females.</p>
          <p>Significant inter- and intrafamilial phenotypic variability has been observed [<xref ref-type="bibr" rid="perrault.REF.jenkinson.2012.974">Jenkinson et al 2012</xref>]. Of note, the variable age of onset and degree of deafness do not depend on the sex of the affected individual.</p>
          <p>SNHL is bilateral and ranges from profound with prelingual (congenital) onset to moderate with early-childhood onset. When onset is in early childhood, hearing loss can be progressive. There is no evidence of impaired vestibular function.</p>
          <p>Only affected females have gonadal dysfunction. Fertility in affected males is reported as normal, although the number of reported individuals is limited.</p>
          <p>Although the ovarian findings in Perrault syndrome were originally described as primary ovarian failure due to absent or streak gonads, subsequent reports identified a spectrum of ovarian dysfunction ranging from gonadal dysgenesis presenting as primary amenorrhea (also known as primary ovarian failure) to ovarian insufficiency (presenting as secondary amenorrhea) which is defined as cessation of menses before age 40 years.</p>
          <p>Some women with Perrault syndrome have had children prior to the onset of ovarian insufficiency [<xref ref-type="bibr" rid="perrault.REF.jenkinson.2012.974">Jenkinson et al 2012</xref>, <xref ref-type="bibr" rid="perrault.REF.jenkinson.2013.605">Jenkinson et al 2013</xref>].</p>
          <p><bold>Other features.</bold> Some individuals have been reported to have additional clinical features. No consistent pattern has been observed with these additional features, which have been reported in more than one case [<xref ref-type="bibr" rid="perrault.REF.jenkinson.2012.974">Jenkinson et al 2012</xref>].</p>
          <p>A spectrum of neurologic features develops over time in some women with the cardinal features of Perrault syndrome, suggesting an underlying neurodegenerative process [<xref ref-type="bibr" rid="perrault.REF.fiumara.2004.246">Fiumara et al 2004</xref>], consistent with the disturbance of mitochondrial homeostasis effected by pathogenic variants in the genes defined to date [<xref ref-type="bibr" rid="perrault.REF.jenkinson.2013.605">Jenkinson et al 2013</xref>]. Data are insufficient to determine whether males display the same neurologic features.</p>
          <list list-type="bullet">
            <list-item>
              <p>Learning difficulties and developmental delay [<xref ref-type="bibr" rid="perrault.REF.jenkinson.2012.974">Jenkinson et al 2012</xref>]</p>
            </list-item>
            <list-item>
              <p>Cerebellar ataxia [<xref ref-type="bibr" rid="perrault.REF.nishi.1988.623">Nishi et al 1988</xref>, <xref ref-type="bibr" rid="perrault.REF.fiumara.2004.246">Fiumara et al 2004</xref>, <xref ref-type="bibr" rid="perrault.REF.kobe.2008.922">Kobe et al 2008</xref>, <xref ref-type="bibr" rid="perrault.REF.jenkinson.2012.974">Jenkinson et al 2012</xref>]</p>
            </list-item>
            <list-item>
              <p>Motor and sensory peripheral neuropathy [<xref ref-type="bibr" rid="perrault.REF.linssen.1994.81">Linssen et al 1994</xref>, <xref ref-type="bibr" rid="perrault.REF.fiumara.2004.246">Fiumara et al 2004</xref>, <xref ref-type="bibr" rid="perrault.REF.kobe.2008.922">Kobe et al 2008</xref>, <xref ref-type="bibr" rid="perrault.REF.marlin.2008.661">Marlin et al 2008</xref>, <xref ref-type="bibr" rid="perrault.REF.jenkinson.2012.974">Jenkinson et al 2012</xref>]</p>
            </list-item>
          </list>
          <p>Skeletal features have been reported in some individuals including high-arched palate, positive thumb and wrist signs, and body disproportion [<xref ref-type="bibr" rid="perrault.REF.jacob.2007.305">Jacob et al 2007</xref>, <xref ref-type="bibr" rid="perrault.REF.ameen.2012.843">Ameen &#x00026; Pinninti 2012</xref>].</p>
        </sec>
        <sec id="perrault.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Sensorineural hearing loss (SNHL) in Perrault syndrome resulting from mutation of <italic toggle="yes">LARS2, HARS2,</italic> or <italic toggle="yes">HSD17B4</italic> is reported to be progressive and of varying severity with onset usually in early childhood and with varying frequencies affected, including reported cases of hearing loss with corresponding upsloping audiograms [<xref ref-type="bibr" rid="perrault.REF.pierce.2013.614">Pierce et al 2013</xref>].</p>
          <p>In contrast, the SNHL in the three families described with biallelic pathogenic variants of <italic toggle="yes">CLPP</italic> was profound and congenital [<xref ref-type="bibr" rid="perrault.REF.jenkinson.2013.605">Jenkinson et al 2013</xref>].</p>
        </sec>
        <sec id="perrault.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance has been complete in all molecularly characterized individuals.</p>
        </sec>
        <sec id="perrault.Nomenclature">
          <title>Nomenclature</title>
          <p>Perrault syndrome has also been referred to as ovarian dysgenesis with sensorineural deafness or XX gonadal dysgenesis with deafness.</p>
          <p>Although <xref ref-type="bibr" rid="perrault.REF.fiumara.2004.246">Fiumara et al [2004]</xref> suggested that Perrault syndrome be classified into type I (static, without neurologic involvement), and type II (with progressive neurologic involvement), families with Perrault syndrome resulting from <italic toggle="yes">CLPP</italic> pathogenic variants have been described both with and without neurologic features, indicating that these are not mutually exclusive categories [<xref ref-type="bibr" rid="perrault.REF.jenkinson.2013.605">Jenkinson et al 2013</xref>].</p>
        </sec>
        <sec id="perrault.Prevalence">
          <title>Prevalence</title>
          <p>Perrault syndrome is rare; fewer than 100 cases have been reported [<xref ref-type="bibr" rid="perrault.REF.kim.2013.e25">Kim et al 2013</xref>]. However, underascertainment is likely significant as males without an affected sister will likely be diagnosed with nonsyndromic deafness, not Perrault syndrome.</p>
        </sec>
      </sec>
      <sec id="perrault.Genetically_Related_Allelic_Dis">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">HARS2, LARS2</italic>, or <italic toggle="yes">CLPP</italic>.</p>
        <p><bold><italic toggle="yes">HSD17B4.</italic></bold> Biallelic loss-of-function pathogenic variants in <italic toggle="yes">HSD17B4</italic> have been identified in individuals with D-bifunctional protein deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/261515">OMIM</ext-link>), a rare single-enzyme disorder of peroxisomal fatty acid beta-oxidation [<xref ref-type="bibr" rid="perrault.REF.van_grunsven.1999.99">van Grunsven et al 1999</xref>] with clinical features similar to those of <related-object link-type="booklink" source-id="gene" document-id="pbd" document-type="chapter">Zellweger syndrome</related-object>.</p>
        <p>D-bifunctional protein deficiency is a severe neurodevelopmental disorder characterized by neonatal hypotonia and seizures within the first days of life. Dysmorphic facies, visual disturbance (with an abnormal electroretinogram), and peripheral neuropathy are common features. Affected infants die in the first two years of life. Brain imaging shows white matter changes; hypoplasia or absence of the corpus callosum; and cerebral and cerebellar hypoplasia. Plasma levels of both very long chain fatty acids (VLCFA) and bile-acid intermediates are abnormally elevated. On immunohistochemistry, peroxisomes are enlarged, but reduced in number.</p>
        <p>Recently an attenuated form of D-bifunctional protein deficiency (type IV) was reported in individuals with compound heterozygous pathogenic variants affecting the hydratase and dehydrogenase domains of the HSD17B4 enzyme [<xref ref-type="bibr" rid="perrault.REF.mcmillan.2012.90">McMillan et al 2012</xref>]. DBP deficiency in this case was characterized by normal early childhood development followed by SNHL, progressive cerebellar and sensory ataxia, and subclinical retinitis pigmentosa. Both DBP hydratase and dehydrogenase activity were markedly decreased, but detectable.</p>
        <p>Subsequently a male with hearing loss, cerebellar ataxia, peripheral neuropathy, and azoospermia caused by compound heterozygous pathogenic variants in <italic toggle="yes">HSD17B4</italic> was reported [<xref ref-type="bibr" rid="perrault.REF.lieber.2014.30">Lieber et al 2014</xref>].</p>
      </sec>
      <sec id="perrault.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>For individuals with Perrault syndrome, other causes of sensorineural hearing loss (SNHL) and ovarian dysfunction need to be excluded before a clinical diagnosis of Perrault syndrome can made with confidence.</p>
        <p><bold>Sensorineural hearing loss</bold> (SNHL) is genetically heterogeneous. See <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Deafness and Hereditary Hearing Loss Overview</related-object> for a detailed differential diagnosis.</p>
        <p><bold>XX gonadal dysgenesis</bold>
<bold>and primary ovarian insufficiency (POI)</bold> are genetically heterogeneous.</p>
        <p><bold>XX gonadal dysgenesis.</bold> For individuals with primary ovarian failure, defined by primary amenorrhea with low estrogen and raised gonadotropins, Turner syndrome (45, X) or other abnormalities of the X chromosome should be excluded by karyotype analysis. Hearing loss is present in approximately 50% of women with Turner syndrome [<xref ref-type="bibr" rid="perrault.REF.king.2007.831">King et al 2007</xref>], but tends to be mild to moderate at higher frequencies [<xref ref-type="bibr" rid="perrault.REF.oliveira.2013.226">Oliveira et al 2013</xref>].</p>
        <p>Testing of genes in which pathogenic variants have been reported to cause ovarian dysgenesis (including <italic toggle="yes">BMP15, FSHR,</italic> and <italic toggle="yes">PSMC3IP/HOP2</italic>) is appropriate.</p>
        <p>Other causes of priomary ovarian failure include 17&#x003b1;-hydroxylase deficiency and 17,20-lysase deficiency; which can be excluded by measurement of 11-deoxycorticosterone and androstenedione levels.</p>
        <p><bold>Primary ovarian insufficiency (POI).</bold> Multiple genetic causes of POI are known. Analysis of a limited number of genes is available by routine clinical testing.</p>
        <list list-type="bullet">
          <list-item>
            <p>Premutation carriers of an expanded <italic toggle="yes">FMR1</italic> allele are at increased risk for ovarian insufficiency; see <related-object link-type="booklink" source-id="gene" document-id="fragilex" document-type="chapter"><italic toggle="yes">FMR1</italic>-Related Disorders</related-object>.</p>
          </list-item>
          <list-item>
            <p>Many females with <related-object link-type="booklink" source-id="gene" document-id="bpes" document-type="chapter">BPES</related-object> (<italic toggle="yes">b</italic>lepharophimosis, <italic toggle="yes">p</italic>tosis, <italic toggle="yes">e</italic>picanthus inversus <italic toggle="yes">s</italic>yndrome), caused by pathogenic variants or deletions of <italic toggle="yes">FOXL2</italic>, have primary ovarian insufficiency. BPES can be distinguished from Perrault syndrome by the presence of marked blepharophimosis and ptosis in BPES.</p>
          </list-item>
          <list-item>
            <p>Mitochondrial DNA depletion syndrome is a genetically and clinically heterogeneous condition. Type 7, caused by biallelic pathogenic variants in <italic toggle="yes">TWNK</italic>, encoding twinkle, is characterized by hypotonia, ataxia, ophthalmoplegia, hearing loss, seizures, and sensory axonal neuropathy. All adolescent females have hypergonadotropic hypogonadism [<xref ref-type="bibr" rid="perrault.REF.l_nnqvist.2009.1553">L&#x000f6;nnqvist et al 2009</xref>].</p>
          </list-item>
          <list-item>
            <p>Ovarian antibodies are increased in polyglandular autoimmune syndrome types 1 and 2.</p>
          </list-item>
        </list>
      </sec>
      <sec id="perrault.Management">
        <title>Management</title>
        <sec id="perrault.Evaluations_Following_Initial_D">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Perrault syndrome, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
            <list-item>
              <p>Endocrinology assessment in women: serum estrogen and gonadotropin (LH and FSH) concentrations. In women with relatively intact ovarian function, serum anti-m&#x000fc;llerian hormone concentrations may provide evidence of incipient ovarian failure [<xref ref-type="bibr" rid="perrault.REF.de_vos.2010.911">De Vos et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>Pelvic imaging in women by ultrasound scan or magnetic resonance imaging to define the presence of ovaries and antral follicle count</p>
            </list-item>
            <list-item>
              <p>Audiologic assessment in men and women to define the degree and frequency range of hearing impairment by audiometry and physiologic tests (as summarized in <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Deafness and Hereditary Hearing Loss Overview</related-object>)</p>
            </list-item>
            <list-item>
              <p>Neurologic assessment to determine if ataxia, peripheral neuropathy, and/or learning disability is present</p>
            </list-item>
          </list>
        </sec>
        <sec id="perrault.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Hearing loss</bold> should be assessed and treated by a multidisciplinary team including an audiologist and otolaryngologist. Possible interventions include hearing aids, vibrotactile devices, and cochlear implantation. Cochlear implantation can be considered in children older than age 12 months with severe-to-profound hearing loss. Provision should be made for any special educational needs.</p>
          <p>Early intervention in young children with profound hearing loss improves cognitive and language development.</p>
          <p><bold>Ovarian insufficiency.</bold> In adolescents presenting with primary amenorrhea, induction of puberty with incremental doses of estrogen should be undertaken in collaboration with a pediatric endocrinologist. In those in whom puberty is complete, cyclic estrogen and progesterone is administered to mimic the menstrual cycle and to trigger withdrawal bleeds. Estrogen can be administered orally or topically.</p>
          <p>Estrogen has a long-term protective effect on bone metabolism and reduces the risk for early-onset osteoporosis. Treatment should last until at least age 50 years to reduce risks of cardiovascular disease and osteoporosis, provided there are no contraindications to estrogen replacement.</p>
          <p>Assisted reproduction through <italic toggle="yes">in vitro</italic> fertilization using donor eggs is a consideration for women with Perrault syndrome. Before considering pregnancy, uterine size should be assessed.</p>
          <p>For women at risk for ovarian insufficiency, oocyte cryopreservation can be considered if ovarian function is sufficiently well preserved to allow for successful harvesting of oocytes.</p>
        </sec>
        <sec id="perrault.Prevention_of_Secondary_Complic">
          <title>Prevention of Secondary Complications</title>
          <p>In consultation with a reproductive endocrinologist, estrogen replacement treatment should be combined with progesterone to reduce the risk for endometrial cancer.</p>
        </sec>
        <sec id="perrault.Surveillance">
          <title>Surveillance</title>
          <p>During induction of puberty, clinical assessment of pubertal staging and adjustment of estrogen dose takes place every three months.</p>
          <p>For adults on maintenance estrogen replacement therapy, assessment of withdrawal bleed pattern and overall well-being should be undertaken on an annual basis and assessment of bone density approximately every five years.</p>
          <p>Routine audiologic assessment is appropriate in individuals who have hearing impairment or are at risk for Perrault syndrome, as hearing loss is often progressive in nature. Audiologic surveillance is not required in individuals with profound hearing loss.</p>
        </sec>
        <sec id="perrault.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>For individuals with hearing loss:</p>
          <list list-type="bullet">
            <list-item>
              <p>Avoid ototoxic medication such as aminoglycosides if alternatives are available.</p>
            </list-item>
            <list-item>
              <p>Avoid exposure to loud noise, which may contribute to deterioration in hearing.</p>
            </list-item>
          </list>
        </sec>
        <sec id="perrault.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate the older and younger sibs of a proband in order to identify as early as possible those who would benefit from treatment and preventive measures (e.g., early intervention in young children with profound hearing loss, estrogen replacement to facilitate pubertal development, and potential oocyte cryopreservation if primary ovarian insufficiency is considered). See <xref ref-type="sec" rid="perrault.Treatment_of_Manifestations">Treatment of Manifestations</xref>.</p>
          <list list-type="bullet">
            <list-item>
              <p>If the pathogenic variants in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk sibs.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variants in the family are not known, screening of siblings should be arranged to include audiologic assessment in males and females and baseline serum measurements of LH and FSH in females.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="perrault.Related_Genetic_Counseling_Issu">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="perrault.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="perrault.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="perrault.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Perrault syndrome is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="perrault.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The unaffected offspring of an individual with Perrault syndrome are obligate heterozygotes (carriers) for a pathogenic variant.</p>
          <p><bold>Other family members.</bold> Each unaffected sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="perrault.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk relatives requires prior molecular identification of the pathogenic variants causing Perrault syndrome in the family.</p>
        </sec>
        <sec id="perrault.Related_Genetic_Counseling_Issu">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="perrault.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The increased risk for primary ovarian insufficiency and infertility in females with Perrault syndrome should be addressed when discussing family planning.</p>
            </list-item>
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="perrault.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk is possible either through a clinical laboratory or a laboratory offering custom prenatal testing. Before offering prenatal testing, it is recommended that both parents of an affected individual be tested to confirm that both are heterozygotes. This is important if the affected individual is a simplex case (i.e., a single occurrence in a family).</p>
          <p>Requests for prenatal testing for conditions which (like Perrault syndrome) do not affect intellect and have some treatment available are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="perrault.Resources">
        <title>Resources</title>
      </sec>
      <sec id="perrault.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="perrault.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>To date mutation of one of four genes &#x02013; <italic toggle="yes">HSD17B4, HARS2, LARS2</italic>, and <italic toggle="yes">CLPP</italic> - has been identified to cause Perrault syndrome. However, the majority of cases of Perrault syndrome are not molecularly defined. <italic toggle="yes">HARS2</italic> and <italic toggle="yes">LARS2</italic> are important for the translation of mitochondrial proteins. In contrast, <italic toggle="yes">CLPP</italic> effects degradation of mitochondrial proteins. It is likely that defects of protein homeostasis in the ear and ovary underlie the pathogenesis of Perrault syndrome.</p>
          <sec id="perrault.HARS2">
            <title>
              <italic toggle="yes">HARS2</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">HARS2</italic> is predicted to be expressed as a number of transcript variants. The longest transcript of 2483 bp (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_012208.3">NM_012208.3</ext-link>) is generated from 13 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="perrault" object-id="perrault.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> A single individual who is compound heterozygous for the <italic toggle="yes">HARS2</italic> pathogenic missense variants c.598C&#x0003e;G and c.1102G&#x0003e;T has been reported [<xref ref-type="bibr" rid="perrault.REF.pierce.2011.6543">Pierce et al 2011</xref>] (<xref ref-type="table" rid="perrault.T.hars2_pathogenic_variants_dis">Table 2</xref>).</p>
            <table-wrap id="perrault.T.hars2_pathogenic_variants_dis" orientation="portrait" position="anchor">
              <label>Table 2 </label>
              <caption>
                <p><italic toggle="yes">HARS2</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_perrault.T.hars2_pathogenic_variants_dis_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_perrault.T.hars2_pathogenic_variants_dis_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_perrault.T.hars2_pathogenic_variants_dis_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_perrault.T.hars2_pathogenic_variants_dis_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.598C&#x0003e;G&#x000a0;<sup>1</sup></td>
                    <td headers="hd_h_perrault.T.hars2_pathogenic_variants_dis_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.(Leu200Val) and alternate splicing&#x000a0;<sup>1</sup></td>
                    <td headers="hd_h_perrault.T.hars2_pathogenic_variants_dis_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_012208.3">NM_012208.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_036340.1">NP_036340.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_perrault.T.hars2_pathogenic_variants_dis_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1102G&#x0003e;T</td>
                    <td headers="hd_h_perrault.T.hars2_pathogenic_variants_dis_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.(Val368Leu)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="perrault.TF.2.1">
                  <label>1. </label>
                  <p>The c.598C&#x0003e;G change created an alternate splice site leading to deletion of 12 codons from the <italic toggle="yes">HARS2</italic> transcript [<xref ref-type="bibr" rid="perrault.REF.pierce.2011.6543">Pierce et al 2011</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">HARS2</italic> encodes mitochondrial histidyl tRNA synthetase 2. Eight protein-coding isoforms of HARS2 have been reported; however, only one of 506 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_036340.1">NP_036340.1</ext-link> encoded by the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_012208.3">NM_012208.3</ext-link> transcript variant) is listed in the Consensus Coding Sequence Project (CCDS).</p>
            <p><bold>Abnormal gene product.</bold> The pathogenic variants in <italic toggle="yes">HARS2</italic> reduced the aminoacylation activity of HARS2 [<xref ref-type="bibr" rid="perrault.REF.pierce.2011.6543">Pierce et al 2011</xref>].</p>
          </sec>
          <sec id="perrault.LARS2">
            <title>
              <italic toggle="yes">LARS2</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">LARS2</italic> is predicted to generate five protein-coding transcripts. The longest transcript of 4744 bp (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_015340.3">NM_015340.3</ext-link>) is generated from 21 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="perrault" object-id="perrault.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> Two individuals with Perrault syndrome have been identified with biallelic pathogenic variants in <italic toggle="yes">LARS2</italic> [<xref ref-type="bibr" rid="perrault.REF.pierce.2013.614">Pierce et al 2013</xref>]: one with a homozygous missense pathogenic variant c.1565C&#x0003e;A, and another with a compound heterozygous frameshift variant c.1077delT and missense variant c.1886C&#x0003e;T (<xref ref-type="table" rid="perrault.T.lars2_pathogenic_variants_dis">Table 3</xref>).</p>
            <table-wrap id="perrault.T.lars2_pathogenic_variants_dis" orientation="portrait" position="anchor">
              <label>Table 3. </label>
              <caption>
                <p><italic toggle="yes">LARS2</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_perrault.T.lars2_pathogenic_variants_dis_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_perrault.T.lars2_pathogenic_variants_dis_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                    <th id="hd_h_perrault.T.lars2_pathogenic_variants_dis_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_perrault.T.lars2_pathogenic_variants_dis_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1077delT</td>
                    <td headers="hd_h_perrault.T.lars2_pathogenic_variants_dis_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.(Ile360PhefsTer15)<break/>(Ile360fsTer)</td>
                    <td headers="hd_h_perrault.T.lars2_pathogenic_variants_dis_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_015340.3">NM_015340.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_056155.1">NP_056155.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_perrault.T.lars2_pathogenic_variants_dis_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1565C&#x0003e;A</td>
                    <td headers="hd_h_perrault.T.lars2_pathogenic_variants_dis_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.(Thr522Asn)</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_perrault.T.lars2_pathogenic_variants_dis_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1886C&#x0003e;T</td>
                    <td headers="hd_h_perrault.T.lars2_pathogenic_variants_dis_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.(Thr629Met)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="perrault.TF.3.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">LARS2</italic> encodes mitochondrial leucyl-tRNA synthetase 2. The longest coding isoform of LARS2 is of 903 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_056155.1">NP_056155.1</ext-link>).</p>
            <p><bold>Abnormal gene product.</bold> The p.(Thr522Asn) variant occurs in a catalytic domain. The p.(Thr629Met) variant is in a site adjacent to a conserved catalytic loop.</p>
          </sec>
          <sec id="perrault.HSD17B4">
            <title>
              <italic toggle="yes">HSD17B4</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">HSD17B4</italic> is predicted to encode seven protein-coding transcripts. The longest transcript of 2899 bp (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001199291.1">NM_001199291.1</ext-link>) is generated from 25 exons. An alternate shorter transcript variant (2710 bp; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000414.3">NM_000414.3</ext-link>; 24 exons) lacks a portion of 5&#x02019; coding region and initiates translation at an alternate start codon compared to the longest variant. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="perrault" object-id="perrault.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> A single individual who is compound heterozygous for the <italic toggle="yes">HSD17B4</italic> nonsense variant c.1704T&#x0003e;A and missense variant c.650A&#x0003e;G has been reported [<xref ref-type="bibr" rid="perrault.REF.pierce.2010.282">Pierce et al 2010</xref>] (<xref ref-type="table" rid="perrault.T.hsd17b4_pathogenic_variants_d">Table 4</xref>).</p>
            <table-wrap id="perrault.T.hsd17b4_pathogenic_variants_d" orientation="portrait" position="anchor">
              <label>Table 4. </label>
              <caption>
                <p><italic toggle="yes">HSD17B4</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_perrault.T.hsd17b4_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_perrault.T.hsd17b4_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_perrault.T.hsd17b4_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_perrault.T.hsd17b4_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.650A&#x0003e;G</td>
                    <td headers="hd_h_perrault.T.hsd17b4_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.(Tyr217Cys)</td>
                    <td headers="hd_h_perrault.T.hsd17b4_pathogenic_variants_d_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000414.3">NM_000414.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000405.1">NP_000405.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_perrault.T.hsd17b4_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1704T&#x0003e;A</td>
                    <td headers="hd_h_perrault.T.hsd17b4_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.(Tyr568Ter)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">HSD17B4</italic> encodes the bifunctional enzyme, hydroxysteroid (17-beta) dehydrogenase 4. The longest coding isoform of HSD17B4 comprises 761 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001186220.1">NP_001186220.1</ext-link>). The shorter alternate isoform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000405.1">NP_000405.1</ext-link>) has 736 amino acid residues.</p>
            <p><bold>Abnormal gene product.</bold> Biallelic loss-of-function pathogenic variants in <italic toggle="yes">HSD17B4</italic> are predicted to cause D-bifunctional protein deficiency. The <italic toggle="yes">HSD17B4</italic> pathogenic nonsense and missense variants in the single individual are predicted to destabilize the dehydrogenase domain [<xref ref-type="bibr" rid="perrault.REF.pierce.2010.282">Pierce et al 2010</xref>].</p>
          </sec>
          <sec id="perrault.CLPP">
            <title>
              <italic toggle="yes">CLPP</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">CLPP</italic> is predicted to generate four protein coding transcripts. The longest transcript of 1194 bp (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_006012.2">NM_006012.2</ext-link>) is generated from six exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="perrault" object-id="perrault.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> Three unrelated families of Pakistani ethnicity have been reported [<xref ref-type="bibr" rid="perrault.REF.jenkinson.2013.605">Jenkinson et al 2013</xref>]. All affected individuals were homozygous: in one family for the missense pathogenic variant c.433A&#x0003e;C; in one family for the missense pathogenic variant c.440G&#x0003e;C, p.(Cys147Ser); and in one family for the splice variant c.270+4A&#x0003e;G.</p>
            <table-wrap id="perrault.T.clpp_pathogenic_variants_disc" orientation="portrait" position="anchor">
              <label>Table 5. </label>
              <caption>
                <p><italic toggle="yes">CLPP</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_perrault.T.clpp_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_perrault.T.clpp_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_perrault.T.clpp_pathogenic_variants_disc_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_perrault.T.clpp_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.270+4A&#x0003e;G</td>
                    <td headers="hd_h_perrault.T.clpp_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_perrault.T.clpp_pathogenic_variants_disc_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_006012.2">NM_006012.2</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_006003.1">NP_006003.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_perrault.T.clpp_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.433A&#x0003e;C</td>
                    <td headers="hd_h_perrault.T.clpp_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.(Thr145Pro)</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_perrault.T.clpp_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.440G&#x0003e;C</td>
                    <td headers="hd_h_perrault.T.clpp_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.(Cys147Ser)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">CLPP</italic> encodes caseinolytic mitochondrial matrix peptidase proteolytic subunit, a component of a mitochondrial ATP-dependent proteolytic complex that includes CLPX. The longest coding isoform of CLPP comprises 277 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_006003.1">NP_006003.1</ext-link>).</p>
            <p><bold>Abnormal gene product.</bold> Crystal-structure modeling suggests that both missense pathogenic variants would alter the structure of the CLPP barrel chamber that captures unfolded or misfolded proteins and exposes them to proteolysis [<xref ref-type="bibr" rid="perrault.REF.jenkinson.2013.605">Jenkinson et al 2013</xref>].</p>
          </sec>
        </sec>
      </sec>
      <sec id="perrault.References">
        <title>References</title>
        <sec id="perrault.Published_GuidelinesConsensus_S">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="perrault.Published_GuidelinesConsensus_S.reflist0">
            <ref id="perrault.REF1">
              <mixed-citation publication-type="web">American College of Medical Genetics. Genetics evaluation guidelines for the etiologic diagnosis of congenital hearing loss. Genetic evaluation of congenital hearing loss expert panel. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110944/">online</ext-link>. 2002. Accessed 1-19-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="perrault.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="perrault.Literature_Cited.reflist0">
            <ref id="perrault.REF.ameen.2012.843">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ameen</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinninti</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>A rare cause for primary amenorrhea: Sporadic Perrault syndrome.</article-title>
                <source>Indian J Endocrinol Metab.</source>
                <year>2012</year>
                <volume>16</volume>
                <fpage>843</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">23087880</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.de_vos.2010.911">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Vos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devroey</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fauser</surname>
                    <given-names>BC</given-names>
                  </name>
                </person-group>
                <article-title>Primary&#x000a0;ovarian&#x000a0;insufficiency.</article-title>
                <source>Lancet.</source>
                <year>2010</year>
                <volume>376</volume>
                <fpage>911</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">20708256</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.fiumara.2004.246">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fiumara</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorge</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toscano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parano</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavone</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opitz</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Perrault syndrome: evidence for progressive nervous system involvement.</article-title>
                <source>Am J Med Genet A</source>
                <year>2004</year>
                <volume>128A</volume>
                <fpage>246</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15216544</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.jacob.2007.305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jacob</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paul</surname>
                    <given-names>TV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathews</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Perrault syndrome with Marfanoid habitus in two siblings.</article-title>
                <source>J Pediatr Adolesc Gynecol</source>
                <year>2007</year>
                <volume>20</volume>
                <fpage>305</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17868898</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.jenkinson.2012.974">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jenkinson</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton-Smith</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reardon</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pearce</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Michele</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conway</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cilliers</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreton</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trump</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>WG</given-names>
                  </name>
                </person-group>
                <article-title>Perrault syndrome: further evidence for genetic heterogeneity.</article-title>
                <source>J Neurol.</source>
                <year>2012</year>
                <volume>259</volume>
                <fpage>974</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22037954</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.jenkinson.2013.605">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jenkinson</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rehman</surname>
                    <given-names>AU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton-Smith</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morell</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drummond</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khan</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naeem</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rauf</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Billington</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schultz</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urquhart</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanley</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cilliers</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kingston</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warner</surname>
                    <given-names>TT</given-names>
                  </name>
                </person-group>
                <article-title>University of Washington Center for Mendelian Genomics, Black GC, Trump D, Davis JR, Ahmad W, Leal SM, Riazuddin S, King MC, Friedman TB, Newman WG. Perrault syndrome&#x000a0;is caused by recessive mutations in CLPP, encoding a mitochondrial ATP-dependent chambered protease.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2013</year>
                <volume>92</volume>
                <fpage>605</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">23541340</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.kim.2013.e25">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chae</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Genotype and phenotype heterogeneity in&#x000a0;perrault syndrome.</article-title>
                <source>J Pediatr Adolesc Gynecol.</source>
                <year>2013</year>
                <volume>26</volume>
                <fpage>e25</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23332201</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.king.2007.831">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makishima</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zalewski</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakalov</surname>
                    <given-names>VK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffith</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bondy</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brewer</surname>
                    <given-names>CC</given-names>
                  </name>
                </person-group>
                <article-title>Analysis of auditory phenotype and karyotype in 200 females with Turner syndrome.</article-title>
                <source>Ear Hear.</source>
                <year>2007</year>
                <volume>28</volume>
                <fpage>831</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">17982369</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.kobe.2008.922">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kobe</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kracht</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmermann</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bachmann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Perrault Syndrome with progressive nervous system involvement.</article-title>
                <source>Clin Nucl Med.</source>
                <year>2008</year>
                <volume>33</volume>
                <fpage>922</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">19033811</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.lieber.2014.30">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lieber</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hershman</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slate</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calvo</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sims</surname>
                    <given-names>KB</given-names>
                  </name>
                </person-group>
                <article-title>Schmahmann JD1, Mootha VK. Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency.</article-title>
                <source>BMC Med Genet.</source>
                <year>2014</year>
                <volume>15</volume>
                <fpage>30</fpage>
                <pub-id pub-id-type="pmid">24602372</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.linssen.1994.81">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Linssen</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Bent</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunner</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poels</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <article-title>Deafness, sensory neuropathy, and ovarian dysgenesis: a new syndrome or a broader spectrum of Perrault syndrome?</article-title>
                <source>Am J Med Genet.</source>
                <year>1994</year>
                <volume>51</volume>
                <fpage>81</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">8030674</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.l_nnqvist.2009.1553">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>L&#x000f6;nnqvist</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paetau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valanne</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pihko</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Recessive twinkle mutations cause severe epileptic encephalopathy.</article-title>
                <source>Brain.</source>
                <year>2009</year>
                <volume>132</volume>
                <fpage>1553</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">19304794</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.marlin.2008.661">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marlin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonard</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leboulanger</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonneau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goizet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Villemeur</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabrol</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houang</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moatti</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldmann</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Denoyelle</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Perrault syndrome: report of four new cases, review and exclusion of candidate genes.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2008</year>
                <volume>146A</volume>
                <fpage>661</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">18241061</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.mcmillan.2012.90">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McMillan</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Worthylake</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartzentruber</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gottlieb</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawrence</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackenzie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beaulieu</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooyer</surname>
                    <given-names>PA</given-names>
                  </name>
                  <collab>FORGE Canada Consortium</collab>
                </person-group>
                <article-title>Wanders RJ, Majewski J, Bulman DE, Geraghty MT, Ferdinandusse S, Boycott KM. Specific combination of compound heterozygous mutations in 17&#x003b2;-hydroxysteroid dehydrogenase type 4 (HSD17B4) defines a new subtype of D-bifunctional protein deficiency.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2012</year>
                <volume>7</volume>
                <fpage>90</fpage>
                <pub-id pub-id-type="pmid">23181892</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.nishi.1988.623">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nishi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kajiyama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawamura</surname>
                    <given-names>I.</given-names>
                  </name>
                </person-group>
                <article-title>The Perrault syndrome: clinical report and review.</article-title>
                <source>Am J Med Genet.</source>
                <year>1988</year>
                <volume>31</volume>
                <fpage>623</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">3067578</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.oliveira.2013.226">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lago</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alves</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Audiological abnormalities in patients with turner syndrome.</article-title>
                <source>Am J Audiol.</source>
                <year>2013</year>
                <volume>22</volume>
                <fpage>226</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">23824435</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.pierce.2011.6543">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pierce</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chisholm</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opitz</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klevit</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in mitochondrial histidyl tRNA synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome.</article-title>
                <source>Proc Natl Acad Sci USA</source>
                <year>2011</year>
                <volume>108</volume>
                <fpage>6543</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21464306</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.pierce.2013.614">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pierce</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gersak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michaelson-Cohen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malach</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klevit</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy-Lahad</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase, lead to premature ovarian failure and hearing loss in Perrault syndrome.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2013</year>
                <volume>92</volume>
                <fpage>614</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">23541342</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.pierce.2010.282">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pierce</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chisholm</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornton</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiumara</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opitz</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy-Lahad</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klevit</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome.</article-title>
                <source>Am J Hum Genet</source>
                <year>2010</year>
                <volume>87</volume>
                <fpage>282</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20673864</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.van_grunsven.1999.99">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Grunsven</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Berkel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooijer</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watkins</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiang</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashimoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoefler</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adamski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Peroxisomal bifunctional protein deficiency revisited: resolution of its true enzymatic and molecular basis.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1999</year>
                <volume>64</volume>
                <fpage>99</fpage>
                <lpage>107</lpage>
                <pub-id pub-id-type="pmid">9915948</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="perrault.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="perrault.Suggested_Reading.reflist0">
            <ref id="perrault.REF.aittom_ki.1995.959">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aittom&#x000e4;ki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucena</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pakarinen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sistonen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tapanainen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gromoll</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaskikari</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sankila</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehvaslaiho</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engel</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nieschlag</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huhtaniemi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de la Chapelle</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure.</article-title>
                <source>Cell</source>
                <year>1995</year>
                <volume>82</volume>
                <fpage>959</fpage>
                <lpage>68</lpage>
                <pub-id pub-id-type="pmid">7553856</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.di_pasquale.2004.106">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Pasquale</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck-Peccoz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Persani</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2004</year>
                <volume>75</volume>
                <fpage>106</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">15136966</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.gottschalk.1996.274">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gottschalk</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coker</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fox</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <article-title>Neurologic anomalies of Perrault syndrome.</article-title>
                <source>Am J Med Genet.</source>
                <year>1996</year>
                <volume>65</volume>
                <fpage>274</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8923934</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.pallister.1979.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pallister</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opitz</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>The Perrault syndrome: autosomal recessive ovarian dysgenesis with facultative, non-sex-limited sensorineural deafness.</article-title>
                <source>Am J Med Genet</source>
                <year>1979</year>
                <volume>4</volume>
                <fpage>239</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">517579</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.perrault.1951.79">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Perrault</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klotz</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Housset</surname>
                    <given-names>E.</given-names>
                  </name>
                </person-group>
                <comment>[Two cases of Turner syndrome with deaf-mutism in two sisters]</comment>
                <source>Bull Mem Soc Med Hop Paris.</source>
                <year>1951</year>
                <volume>67</volume>
                <fpage>79</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">14821788</pub-id>
              </element-citation>
            </ref>
            <ref id="perrault.REF.zangen.2011.572">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zangen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaufman</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeligson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perlberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fridman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanaan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdulhadi-Atwan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abu Libdeh</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gussow</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kisslov</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carmel</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renbaum</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy-Lahad</surname>
                    <given-names>E.</given-names>
                  </name>
                </person-group>
                <article-title>XX ovarian dysgenesis is caused by a PSMC3IP/HOP2 mutation that abolishes coactivation of estrogen-driven transcription.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2011</year>
                <volume>89</volume>
                <fpage>572</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21963259</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="perrault.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="perrault.Author_Notes">
          <title>Author Notes</title>
          <p>Bill Newman is Professor of Translational Genomic Medicine at the University of Manchester. His main interests are in applying new technologies in clinical practice, the characterization of rare diseases and pharmacogenetics.Web: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.manchester.ac.uk/research/William.newman/">www.manchester.ac.uk/research/William.newman</ext-link></p>
          <p>Tom Friedman is Chief of the Laboratory of Molecular Genetics at the NIDCD/NIH. His goal is to identify and study the functions of genes associated with syndromic and nonsyndromic forms of deafness.</p>
          <p>Gerard Conway is Professor of Reproductive Endocrinology at the Institute of Women&#x02019;s Health, University College London, UK. His clinical research interests are in the fields of reproductive endocrinology and disorders of development.</p>
        </sec>
        <sec id="perrault.Acknowledgments">
          <title>Acknowledgments</title>
          <p>Prof Newman&#x02019;s work is supported by Action on Hearing Loss. Prof Friedman is supported by the Intramural Program of the NIDCD.</p>
        </sec>
        <sec id="perrault.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>25 September 2014 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>10 March 2014 (bn) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
